VTVT vTv Therapeutics Inc.

1.61
-0.08  -5%
Previous Close 1.69
Open 1.65
Price To Book -1.56
Market Cap 68627971
Shares 42,626,069
Volume 105,924
Short Ratio
Av. Daily Volume 3,796,679

SEC filingsSee all SEC filings

  1. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 181231160
  2. 8-K - Current report 181229384
  3. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 181211508
  4. 8-K - Current report 181211505
  5. 8-K - Current report 181170791

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 part of trial to be initiated April 2018.
TTP399
Type 1 Diabetes
Phase 2 data released August 2016. Primary endpoint met.
TTP399 - AGATA
Type 2 Diabetes
Phase 2 primary endpoint met - December 14, 2016.
TTP273 - LOGRA
Type 2 Diabetes
Phase 3 data both Part A (April 9, 2018) and Part B (June 12, 2018) did not meet endpoints.
Azeliragon - STEADFAST
Mild Alzheimer’s disease

Latest News

  1. Detailed Research: Economic Perspectives on Honeywell International, Tabula Rasa Healthcare, El Pollo Loco, Acceleron Pharma, vTv Therapeutics, and 22nd Century Group — What Drives Growth in Today's Competitive Landscape
  2. vTv Therapeutics to Present at the 30th Annual Piper Jaffray Healthcare Conference
  3. VTv Therapeutics (VTVT) Reports Q3 Loss, Tops Revenue Estimates
  4. VTv Therapeutics: 3Q Earnings Snapshot
  5. vTv Therapeutics Announces Third Quarter 2018 Results and Update
  6. VTv Therapeutics (VTVT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
  7. vTv Therapeutics Announces Transfer of Listing to The Nasdaq Capital Market
  8. vTv Therapeutics Presents Positive Data on the Effect of Azeliragon in Patients with Alzheimer’s and Diabetes at the 11th Clinical Trials on Alzheimer’s Disease (CTAD) Conference
  9. Factors of Influence in 2018, Key Indicators and Opportunity within Tabula Rasa Healthcare, Interpublic Group of Companies, Travelport Worldwide, Weight Watchers International, vTv Therapeutics, and Ulta Beauty — New Research Emphasizes Economic Growth
  10. Stock Market News Daily Roundup October 17
  11. Today's Research Reports on Trending Tickers: vTv Therapeutics and Johnson & Johnson
  12. vTv Therapeutics to Deliver Two Presentations at the 11th Clinical Trials on Alzheimer’s Disease (CTAD) Conference
  13. vTv Therapeutics Shares Soar in October, Near Term Catalysts, Analysts review and Target
  14. vTv Therapeutics (VTVT) Looks Good: Stock Adds 5.8% in Session
  15. This Week’s Biotech and Cannabis Stocks to Watch
  16. Today’s Research Reports on Stocks to Watch: Trevena and vTv Therapeutics
  17. Undervalued Stocks You Can’t Afford to Miss
  18. Today’s Research Reports on Stocks to Watch: Inovio Pharmaceuticals and vTV Therapeutics
  19. vTv Therapeutics to Present at the 20th Annual Rodman & Renshaw Global Investment Conference